- Previous Close
1,066.90 - Open
1,057.20 - Bid 1,080.00 x --
- Ask 1,077.90 x --
- Day's Range
1,054.50 - 1,137.60 - 52 Week Range
494.70 - 1,197.00 - Volume
8,507 - Avg. Volume
8,912 - Market Cap (intraday)
22.739B - Beta (5Y Monthly) 0.37
- PE Ratio (TTM)
37.04 - EPS (TTM)
29.29 - Earnings Date --
- Forward Dividend & Yield 5.50 (0.51%)
- Ex-Dividend Date Sep 17, 2024
- 1y Target Est
--
Windlas Biotech Limited, a contract development and manufacturing organization (CDMO), manufactures and trades in pharmaceutical products in India and internationally. The company offers CDMO solutions, including product development, licensing, and commercial manufacturing of complex drugs and dosage forms. It also produces nutraceutical supplement products. In addition, the company manufactures tablets, capsules, pouches, sachets, and liquid bottles; and generic products portfolio comprising fixed dosage combinations, fixed dosage plus modified release combinations, customized generics, chewable or dispersible, and plain oral solids. Windlas Biotech Limited was incorporated in 2001 and is based in Gurugram, India.
windlas.com1,154
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: WINDLAS.BO
View MorePerformance Overview: WINDLAS.BO
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: WINDLAS.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: WINDLAS.BO
View MoreValuation Measures
Market Cap
22.74B
Enterprise Value
20.78B
Trailing P/E
37.04
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.15
Price/Book (mrq)
4.83
Enterprise Value/Revenue
2.86
Enterprise Value/EBITDA
19.23
Financial Highlights
Profitability and Income Statement
Profit Margin
8.47%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
7.28B
Net Income Avi to Common (ttm)
617.06M
Diluted EPS (ttm)
29.29
Balance Sheet and Cash Flow
Total Cash (mrq)
2.13B
Total Debt/Equity (mrq)
4.02%
Levered Free Cash Flow (ttm)
--